All
Making Something Positive out of Breast Cancer
After my breast cancer treatment, I started a clothing bank to give others free access to recovery items like post-surgery shirts and pillows.
Ovarian Cancer Treatment Side Effects Make for a Difficult Balancing Act
I urge researchers to look into why side effects occur in cancer drugs and to find ways to mitigate them that doesn’t impact their efficacy.
GLP-1 Drugs Linked to Fewer Obesity-Related Cancers
GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.
Breaking Down Treatment Variables in AYA Patients With Cancer
Dr. Andrew M. Evens discussed the importance of differentiating AYA cancers from other age groups, specifically focusing on lymphoma care.
Itovebi Triplet Combo Boosts Survival in HR+, HER2– Breast Cancer
Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.
Zepzelca Plus Tecentriq Boosts Survival in First-Line ES-SCLC Care
Among patients with ES-SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.
Expert Offers Surveillance, Lifestyle Guidance After CRC, Anal Cancer
Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.
Contemplating AI Assistance as a Cancer Survivor
When I saw a study about using AI facial recognition in cancer decision-making headlines, I decided to try my own informal, non-scientific experiment.
FDA's ODAC Votes Against Targeted Therapies in Bladder and Prostate Cancer
The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate cancer, respectively.
PMB-CT01 Therapy Induces Complete Remission in Follicular Lymphoma
A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.
Intra-Arterial Paraplatin Shows No Hearing Loss in Retinoblastoma
DPOAE testing showed no hearing loss in children with retinoblastoma treated with intra-arterial paraplatin, suggesting preserved cochlear function.
A Trailblazer in Oncology Nursing and Research
Gayle S. Jameson, M.S.N, ACNP-BC, AOCN, is a trailblazer whose expertise and compassion have made a profound impact on oncology care.
Evolving Myelofibrosis Treatments Aims to Fill Unmet Needs
JAK inhibitors ease symptoms in myelofibrosis, but only stem cell transplant offers a cure; newer drugs aim to fill unmet needs, especially for anemia.
Understanding the Evolution of Waldenström Macroglobulinemia Treatment
Dr. Shirley D’Sa discusses how treatment strategies for WM have evolved over the course of her career.
When Others say Your Own Thoughts About Cancer Aloud
I'm a follicular lymphoma survivor, and hearing others name the quiet, lasting changes of life after cancer made me feel seen and understood.
FDA’s ODAC Casts Votes on the Use of Certain Treatment Options in Cancer Care
The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma patient populations, respectively.
FDA Grants Fast Track Designation to ZL-1310 in Small Cell Lung Cancer
ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage in most patients treated.
Sixteen Years With Leukemia Taught Me to Savor Life
I’ve lived with large granular lymphocytic leukemia for 16 years and have learned to spend my energy wisely, embrace palliative care and choose joy over anger.
Finding Meaning After an Acute Myeloid Leukemia Diagnosis
I found purpose after my AML diagnosis by reflecting on loss, embracing gratitude and using my experience to help others through their own cancer journeys.
Early Arterial Thrombosis May Signal Future Cancer Risk
Arterial thrombosis may occur years before cancer diagnosis, suggesting it could be a risk factor, according to Dr. Tiziano Barbui.
What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer?
Proton therapy may reduce urinary, bowel and sexual side effects in prostate cancer by minimizing radiation exposure to healthy tissue, per Dr. Curtiland Deville Jr.
The Unnamed Nurse who Saved My Life During Breast Cancer
I’ll never forget the unnamed nurse who stayed calm and gentle while treating me during a dangerous post-surgery infection that could have ended my life.
Acoustic Cluster Therapy Shows Benefit in Colorectal Liver Metastases
Tumors shrank more with the addition of acoustic cluster therapy to chemotherapy in colorectal liver metastases in the phase 1 ACTIVATE trial.
Prostate Cancer Treatment Options: Common Questions in Focal Therapy, Surgery
Dr. Kelly Stratton answered the most frequently asked questions in prostate cancer regarding localized prostate cancer care, including surgery and focal therapy.
With Cancer in Remission, What Is the New Normal for Patients?
CURE spoke with experts about what life is like for patients in the survivorship care period.
Younger Patients With Lung Cancer Often Have Targetable Biomarkers
Younger patients with lung cancer are more likely to have mutations that allow for targeted therapies, which can lead to more personalized and effective treatment.
Facing Cancer as an AYA and Navigating Fertility Preservation Choices
Carly Stafford Dixon, discusses how she approached fertility preservation after her diagnosis of primary mediastinal b-cell lymphoma, a rare blood cancer.
What Patients Should Know About a Melanoma Diagnosis
Melanoma care varies by stage, with early cases being treated with surgery, whereas advanced disease often requires immunotherapy or targeted therapy.
Reflecting on my Son's Graduation as a Previvor
As a Lynch syndrome previvor, I feel deep gratitude to witness my son’s graduation — a milestone my brother never lived to see with his own child.
Answers to Frequently Asked Questions About Prostate Cancer Risk, Treatment
Dr. Kelly Stratton answers the most frequently asked questions in prostate cancer regarding risk for recurrence, progression and treatment options.